Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Five PD-1-Related Questions for Suzanne L. Topalian, MD

November 5th 2012

Suzanne L. Topalian, MD, has led clinical development of monoclonal antibodies to treat patients with melanoma and other solid tumors, including those targeting the PD-1 T cell co-receptor.

Amid Setbacks, Efforts to Target Aurora Kinases Persist

November 1st 2012

The development of targeted agents aimed at aurora kinases has proceeded slowly, and the future may lie in combination therapies.

Potential Biomarker for Response to Bevacizumab in Colorectal Cancer Identified

October 25th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Tracking the Oncology Pipeline: Developments From ESMO

October 25th 2012

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

October 22nd 2012

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

City of Hope: Boldly Traversing the "Valley of Death"

October 19th 2012

Founded in 1913 as a tuberculosis sanatorium, City of Hope today enjoys a reputation as a leading research, treatment, and education center for those with cancer, diabetes, and other life-threatening diseases.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

October 2012: Trials in Progress

October 18th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Putting the Genome to Work in Breast Cancer

October 18th 2012

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Evolving Biologic Diversity Generates New Challenges

October 16th 2012

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

Five MEK-Related Questions for Jeffrey S. Weber, MD, PhD

October 12th 2012

Jeffrey S. Weber, MD, PhD, specializes in cancer immunotherapy and has been involved in numerous trials of clinical drug development, vaccines, and studies on autoimmunity and melanoma.

The Secret to Success: Eliciting a Thorough Cancer Family History

October 11th 2012

A thorough personal and family history is the key to determining which patients are candidates for genetic counseling and testing.

Dr. Camidge on the Evolution of Clinical Cancer Research

October 11th 2012

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the ever changing and evolving world of clinical cancer research.

The MEK Junction: Protein Presents a Ripe Target for Inhibitors

October 11th 2012

Though located far downstream of the extracellular trigger that initiates its signaling pathway, the MEK protein is no less significant a player in the cascade of events that promotes key cellular processes.

Dr. Ribas on Combining Vemurafenib and Ipilimumab

October 9th 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

Urology Practices Form Collaborative Partnerships With Specialty Pharmacy Providers

October 9th 2012

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

Molecular Discoveries Pave Way for Rapid Advances in Lung Cancer

October 5th 2012

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

Supercomputer Network Allows for Faster Genomic Analysis

October 4th 2012

A new supercomputer-based network will allow physicians to transfer and analyze genomic data more rapidly than standard methods.

BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma

September 29th 2012

Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.